Seven Eight Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Seven Eight Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-25,809	Closed	-$3.86M	–	678
2024 Q1	$3.86M	Buy	25,809 +20,572	+393%	+$3.43M	0.4%	61
2023 Q4	$1M	Buy	+5,237	New	+$892K	0.12%	253
2023 Q2	–	Sell	-2,320	Closed	-$465K	–	484
2023 Q1	$465K	Buy	+2,320	New	+$488K	0.1%	254
2022 Q4	–	Sell	-4,921	Closed	-$985K	–	401
2022 Q3	$985K	Buy	+4,921	New	+$939K	0.2%	159
2022 Q2	–	Sell	-1,764	Closed	-$288K	–	380
2022 Q1	$288K	Buy	+1,764	New	+$269K	0.04%	416
2019 Q4	–	Sell	-6,684	Closed	-$538K	–	613
2019 Q3	$538K	Buy	+6,684	New	+$529K	0.03%	509
2018 Q3	–	Sell	-10,484	Closed	-$1.03M	–	560
2018 Q2	$1.03M	Buy	+10,484	New	+$1.04M	0.07%	280
2017 Q4	–	Sell	-21,584	Closed	-$2.54M	–	444
2017 Q3	$2.54M	Buy	+21,584	New	+$1.84M	0.31%	109
2016 Q2	–	Sell	-2,700	Closed	-$169K	–	529
2016 Q1	$169K	Buy	2,700 +1,800	+200%	+$120K	0.07%	329
2015 Q4	$85K	Buy	+900	New	+$83.4K	0.06%	376
2015 Q3	–	Sell	-400	Closed	-$48K	–	521
2015 Q2	$48K	Sell	400 -800	-67%	-$95.6K	0.06%	335
2015 Q1	$125K	Buy	+1,200	New	+$122K	0.21%	171

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Seven Eight Capital's ALNY Position: Q2 2024 in Review

Seven Eight Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 25,809 shares — an estimated $3.86M sold.

Seven Eight Capital first reported a position in ALNY in Q1 2015 and held it in 12 quarters. The position peaked at $3.86M in Q1 2024. 522 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

Seven Eight Capital reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Seven Eight Capital sold 25,809 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $3.86M.
Seven Eight Capital first reported a position in Alnylam Pharmaceuticals in Q1 2015 and held it in 12 quarters.
Seven Eight Capital's Alnylam Pharmaceuticals position peaked at $3.86M in Q1 2024.
522 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.